Search Results - "OTTMANN, Oliver G"

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies by Romanski, Annette, Uherek, Christoph, Bug, Gesine, Seifried, Erhard, Klingemann, Hans, Wels, Winfried S., Ottmann, Oliver G., Tonn, Torsten

“…Many B‐cell acute and chronic leukaemias tend to be resistant to killing by natural killer (NK) cells. The introduction of chimeric antigen receptors (CAR)…”
Get full text

Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma by Oelsner, Sarah, Friede, Miriam E, Zhang, Congcong, Wagner, Juliane, Badura, susanne, Bader, Peter, Ullrich, Evelyn, Ottmann, Oliver G, Klingemann, Hans, Tonn, Torsten, Wels, Winfried S

“…Abstract Background aims Natural killer (NK) cells can rapidly respond to transformed and stressed cells and represent an important effector cell type for…”
Get full text

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia by Gökbuget, Nicola, Zugmaier, Gerhard, Klinger, Matthias, Kufer, Peter, Stelljes, Matthias, Viardot, Andreas, Horst, Heinz A, Neumann, Svenja, Brüggemann, Monika, Ottmann, Oliver G, Burmeister, Thomas, Wessiepe, Dorothea, Topp, Max S, Bargou, Ralf

Get full text

Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation by Pfeifer, Heike, Raum, Katharina, Markovic, Sandra, Nowak, Verena, Fey, Stephanie, Obländer, Julia, Pressler, Jovita, Böhm, Verena, Brüggemann, Monika, Wunderle, Lydia, Hüttmann, Andreas, Wäsch, Ralph, Beck, Joachim, Stelljes, Matthias, Viardot, Andreas, Lang, Fabian, Hoelzer, Dieter, Hofmann, Wolf-Karsten, Serve, Hubert, Weiss, Christel, Goekbuget, Nicola, Ottmann, Oliver G., Nowak, Daniel

“…We investigated the role of copy number alterations to refine risk stratification in adult Philadelphia chromosome positive (Ph)+ acute lymphoblastic leukemia…”
Get full text

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL by Kantarjian, Hagop, Giles, Francis, Wunderle, Lydia, Bhalla, Kapil, O'Brien, Susan, Wassmann, Barbara, Tanaka, Chiaki, Manley, Paul, Rae, Patricia, Mietlowski, William, Bochinski, Kathy, Hochhaus, Andreas, Griffin, James D, Hoelzer, Dieter, Albitar, Maher, Dugan, Margaret, Cortes, Jorge, Alland, Leila, Ottmann, Oliver G

“…This phase 1 study treated 119 patients with imatinib-resistant chronic myelogenous leukemia (CML) with nilotinib, an inhibitor of BCR-ABL tyrosine kinase. The…”
Get full text

Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat by Oppliger Leibundgut, Elisabeth, Haubitz, Monika, Burington, Bart, Ottmann, Oliver G, Spitzer, Gary, Odenike, Olatoyosi, McDevitt, Michael A, Röth, Alexander, Snyder, David S, Baerlocher, Gabriela M

“…In a phase-2 study, the telomerase inhibitor imetelstat induced rapid hematologic responses in all patients with essential thrombocythemia who were refractory…”
Get full text

Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia by Badura, Susanne, Tesanovic, Tamara, Pfeifer, Heike, Wystub, Sylvia, Nijmeijer, Bart A, Liebermann, Marcus, Falkenburg, J H Frederik, Ruthardt, Martin, Ottmann, Oliver G

“…Aberrant PI3K/AKT/mTOR signaling has been linked to oncogenesis and therapy resistance in various malignancies including leukemias. In Philadelphia chromosome…”
Get full text

Bim and Bad Mediate Imatinib-Induced Killing of Bcr/Abl⁺ Leukemic Cells, and Resistance Due to Their Loss Is Overcome by a BH3 Mimetic by Kuroda, Junya, Puthalakath, Hamsa, Cragg, Mark S., Kelly, Priscilla N., Bouillet, Philippe, Huang, David C. S., Kimura, Shinya, Ottmann, Oliver G., Druker, Brian J., Villunger, Andreas, Roberts, Andrew W., Strasser, Andreas

“…Cell killing is a critical pharmacological activity of imatinib to eradicate Bcr/Abl⁺ leukemias. We found that imatinib kills Bcr/ Abl⁺ leukemic cells by…”
Get full text

Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies by Jabbour, Elias, Ottmann, Oliver G, Deininger, Michael, Hochhaus, Andreas

“…The phosphoinositide 3-kinase pathway represents an important anticancer target because it has been implicated in cancer cell growth, survival, and motility…”
Get full text

Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) by Ottmann, Oliver G, Pfeifer, Heike

“…The tyrosine kinase inhibitor (TKI) imatinib has become an integral part of front-line therapy for Ph(+) ALL, with remission rates exceeding 90% irrespective…”
Get full text

A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia by Lang, Fabian, Wunderle, Lydia, Badura, Susanne, Schleyer, Eberhard, Brüggemann, Monika, Serve, Hubert, Schnittger, Susanne, Gökbuget, Nicola, Pfeifer, Heike, Wagner, Sebastian, Ashelford, Kevin, Bug, Gesine, Ottmann, Oliver G

“…Abstract Background Combined inhibition of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) complexes may be an efficient…”
Get full text

CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells by Legut, Mateusz, Dolton, Garry, Mian, Afsar Ali, Ottmann, Oliver G., Sewell, Andrew K.

“…Adoptive transfer of T cells genetically modified to express a cancer-specific T-cell receptor (TCR) has shown significant therapeutic potential for both…”
Get full text

Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL–positive leukemic cells by Tanaka, Ruriko, Squires, Matthew S., Kimura, Shinya, Yokota, Asumi, Nagao, Rina, Yamauchi, Takahiro, Takeuchi, Miki, Yao, Hisayuki, Reule, Matthias, Smyth, Tomoko, Lyons, John F., Thompson, Neil T., Ashihara, Eishi, Ottmann, Oliver G., Maekawa, Taira

“…Despite promising clinical results from imatinib mesylate and second-generation ABL tyrosine kinase inhibitors (TKIs) for most BCR-ABL+ leukemia, BCR-ABL…”
Get full text

TKI vs relapse after HSCT: is the jury still out? by Ottmann, Oliver G.

Get full text

Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial by Döhner, Hartmut, Symeonidis, Argiris, Deeren, Dries, Demeter, Judit, Sanz, Miguel A., Anagnostopoulos, Achilles, Esteve, Jordi, Fiedler, Walter, Porkka, Kimmo, Kim, Hee‐Je, Lee, Je‐Hwan, Usuki, Kensuke, D'Ardia, Stefano, Won Jung, Chul, Salamero, Olga, Horst, Heinz‐August, Recher, Christian, Rousselot, Philippe, Sandhu, Irwindeep, Theunissen, Koen, Thol, Felicitas, Döhner, Konstanze, Teleanu, Veronica, DeAngelo, Daniel J., Naoe, Tomoki, Sekeres, Mikkael A., Belsack, Valerie, Ge, Miaomiao, Taube, Tillmann, Ottmann, Oliver G.

“…In this phase 3 trial, older patients with acute myeloid leukemia ineligible for intensive chemotherapy were randomized 2:1 to receive the polo‐like kinase…”
Get full text

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) by Wassmann, Barbara, Pfeifer, Heike, Stadler, Michael, Bornhaüser, Martin, Bug, Gesine, Scheuring, Urban J., Brück, Patrick, Stelljes, Matthias, Schwerdtfeger, Rainer, Basara, Nadezda, Perz, Jolanta, Bunjes, Donald, Ledderose, Georg, Mahlberg, Rolf, Binckebanck, Anja, Gschaidmeier, Harald, Hoelzer, Dieter, Ottmann, Oliver G.

“…In adult Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), minimal residual disease (MRD) after stem cell transplantation (SCT) is…”
Get full text

Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation by Hofmann, Wolf-K., Jones, Letetia C., Lemp, Nathan A., de Vos, Sven, Gschaidmeier, Harald, Hoelzer, Dieter, Ottmann, Oliver G., Koeffler, H. Phillip

“…The tyrosine kinase inhibitor STI571 is a promising agent for the treatment of advanced Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia…”
Get full text

Treatment of patients with advanced cancer with the natural killer cell line NK-92 by Tonn, Torsten, Schwabe, Dirk, Klingemann, Hans G, Becker, Sven, Esser, Ruth, Koehl, Ulrike, Suttorp, Meinolf, Seifried, Erhard, Ottmann, Oliver G, Bug, Gesine

“…Abstract Background aims Natural killer (NK) cells, either naive or genetically engineered, are increasingly considered for cellular therapy of patients with…”
Get full text

Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia by Romanski, Annette, Bug, Gesine, Becker, Sven, Kampfmann, Manuela, Seifried, Erhard, Hoelzer, Dieter, Ottmann, Oliver G., Tonn, Torsten

“…Natural killer (NK) cell-mediated cytotoxicity contributes to the innate immune response against numerous malignancies, including leukemias. Acute…”
Get full text

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL by Rousselot, Philippe, Coudé, Marie Magdelaine, Gokbuget, Nicola, Gambacorti Passerini, Carlo, Hayette, Sandrine, Cayuela, Jean-Michel, Huguet, Françoise, Leguay, Thibaut, Chevallier, Patrice, Salanoubat, Celia, Bonmati, Caroline, Alexis, Magda, Hunault, Mathilde, Glaisner, Sylvie, Agape, Philippe, Berthou, Christian, Jourdan, Eric, Fernandes, José, Sutton, Laurent, Banos, Anne, Reman, Oumedaly, Lioure, Bruno, Thomas, Xavier, Ifrah, Norbert, Lafage-Pochitaloff, Marina, Bornand, Anne, Morisset, Laure, Robin, Valérie, Pfeifer, Heike, Delannoy, Andre, Ribera, Josep, Bassan, Renato, Delord, Marc, Hoelzer, Dieter, Dombret, Herve, Ottmann, Oliver G.

“…Prognosis of Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) in the elderly has improved during the imatinib era. We investigated dasatinib,…”
Get full text